Gore Receives FDA Approval for Endovascular Treatment of In-Stent Restenosis with the GORE VIABAHN Endoprosthesis

Innovative treatment offers long-term solution for ISR

September 22, 2014 — FLAGSTAFF, Ariz. — W. L. Gore & Associates, Inc. (Gore) today announced that the Food and Drug Administration (FDA) has approved the Gore Viabahn Endoprosthesis for interventional treatment of in-stent restenosis in the superficial femoral artery (SFA). Now indicated for the treatment of failed bare metal stents (BMS) in the SFA, the Gore Viabahn Device has more vascular indications supported by more level 1 clinical trials than any other self-expanding peripheral stent or stent-graft.

American College of Cardiology Updates Heart Attack Recommendations

WASHINGTON (Sept. 22, 2014) —In response to new science showing that complete revascularization of all significantly blocked arteries leads to better outcomes in some heart attack patients, the American College of Cardiology has withdrawn its Choosing Wisely recommendation that patients and caregivers examine whether this practice is truly necessary.

Medtronic Announces CE Mark and European Launch of TYRX Absorbable Antibacterial Envelope

MINNEAPOLIS - Sept. 22, 2014 - Medtronic, Inc. has received CE (Conformité Européenne) Mark for the TYRX Absorbable Antibacterial Envelope, a mesh envelope that covers an implantable cardiac device to help stabilize the device after implantation and reduce surgical-site infections.

First-in-Man Procedure Utilizes a New Method of Stem Cell Delivery: ND Infusion Catheter

ND® Infusion Catheter’s unique design preserves cell viability and facilitates stem cell delivery

ND® Infusion Catheter

ND® Infusion Catheter

STENTYS Stent continues to show low mortality two years after treatment of a heart attack

Final 2 Year Results from APPOSITION III Study Presented at TCT Conference in Washington, D.C.

PRINCETON, N.J. and PARIS – September 16, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing stent to treat acute myocardial infarction (AMI), today announced the results of the 1,000 patient APPOSITION III clinical study at two years after th e treatment of a severe heart attack.

Latest Data Shows OrbusNeich’s COMBO™ Dual Therapy Stent has Excellent Healing Benefits

The world’s first and only dual therapy stent
WASHINGTON, D.C., [September 18, 2014] – Prof. Stephen W.L. Lee presented two-year optical coherence tomography (OCT) findings and three-year clinical follow up from the EGO COMBO study, providing further evidence to support the healing benefits of the COMBO Dual Therapy Stent, the only drug eluting stent (DES) with active EPC capture technology. The findings were presented during the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, held in Washington, D.C., September 13-17, 2014.

MedCure Now Offers Perfused Fresh Tissue Models: Simulated Vascular Processes Facilitate Enhanced Learning Environment for Medical World

PORTLAND, Oregon, Aug. 27, 2014 – After three years in development, MedCure, Inc. has perfected a technique that mimics functioning circulatory system processes in cadaveric specimens. By perfusing fresh tissue models, this surgical simulation service, dubbed Pulsatile Anatomical Trainer (PAT™), elevates cadaveric work beyond its traditionally inert, anatomy-driven application.

Clinical Trial Results for Impella RP Right Ventricular Heart Failure Trial, RECOVER RIGHT, Released at TCT 2014

WASHINGTON, DC – September 16, 2014 -- Abiomed Inc. today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System.  The clinical trial results demonstrated a survival rate of 73% in the overall patient population.

3D-Printed HeartPrint® Model Helps 16-Year-Old Heart Tumor Patient

September 16, 2014 — Materialise, a pioneer in 3D Printing for medical applications, recently created a 3D-printed heart model for doctors at Cincinnati Children’s Hospital to support Bradley White’s case, a 16-year-old boy who was born with a tumor. With the aid of Materialise’s HeartPrint® 3D-printed model, his doctors were able to determine the best treatment for Bradley’s erratic heartbeat.

Watch the video at http://vimeo.com/105851371

Back to top